ERRATA

Following is a list of errata and corrections to *USP–NF*. The page number indicates where the item is found and in which official or pending official publication of *USP–NF*. This list will be updated with the posting of errata reports on www.usp.org/USPNF/newOfficialText. This information will appear in its corrected form in a future annual edition of *USP–NF*. An erratum consists of content erroneously published that does not accurately reflect the intended official or effective requirements as approved by the Council of Experts. USP staff is available to respond to questions regarding the accuracy of a particular requirement by calling 1-800-822-USPC.

Page Number	Title	Section	Description
USP34–NF29			
151	⟨401⟩ *Fats and Fixed Oils*	*Omega-3 Fatty Acids Determination and Profile*	Line 4 of both *Test Solution 2* and *Test Solution 3* and line 5 under *Standard Solution 1*, after the sentence ending in "to volume": Add "Gentle heating (up to 60°) may be applied to obtain a clear solution."
			Line 24 and line 45 of *Procedure*: Change "$(r_{U2}/r_{T2}–r_{U1}/r_{T1}) \times r_{T2}$" to: $1/(r_{U2}/r_{T2}–r_{U1}/r_{T1})$
		Content of Total Omega-3 Acids	Lines 12, 16, and 20: Change "*Test Solution 3*" to: *Test Solution 4*
243	⟨621⟩ *Chromatography*	*Definitions and Interpretation of Chromatograms*	Line 4 of *Hold-Up Volume* (V_M): Change "mm/min" to: mL/min
			Line 5 of *Relative Retardation* (R_{ret}): Change "$R_{rel} = b / c$" to: $R_{ret} = b / c$
530	⟨1053⟩ *Capillary Electrophoresis*	*Micellar Electrokinetic Chromatography (MEKC), Principle*	Paragraph 3, line 8 (formula) and line 12: Change "t_m" to: t_{mc}
			Paragraph 4, line 3 (formula): Change "t_m" to: t_{mc}
		Electrolytic Solution Parameters, Surfactant Type and Concentration	Line 7 (formula): Change"t_m" to: t_{mc}
843	⟨1788⟩ *Methods for the Determination of Particulate Matter in Injections and Ophthalmic Solutions*	*Light Obscuration Particle Count Test, Sensor Resolution*	Paragraph 2, line 20 of *Manual Method*: Change "Calculate the percentage of resolution of the sensor by the formula: $100\left(\sqrt{S_O^2 - S_S^2/D}\right)$ in which S_O is the highest observed standard deviation determined for the sphere; S_S is the supplier's reported standard deviation for the spheres; and D is the diameter, in µm, of the spheres as specified by the supplier. The resolution is not more than 10%." to: One commonly used method for calculating the percentage of resolution of the sensor is the following: % resolution = $(100/D) \times [(S_{Obs})^2 - (S_{Std})^2]^{1/2}$ in which S_{Obs} is the highest observed standard deviation determined for the sphere standard; S_{Std} is the supplier's reported standard deviation for the spheres; and D is the diameter, in µm, of the spheres as specified by the supplier. The resolution is not more than 10%.
927	*Iodine Monobromide*	CAS Number	Change: "*[7789-35-5]*" to: *[7789-33-5]*
940	*Potassium Ferrocyanide* $K_4Fe(CN)_6 \cdot 3H_2O$	CAS Number	Change: "*[13943-58-3]*" to: *[14459-95-1]*
1115	*Cod Liver Oil Capsules*	*Other requirements*	Line 2: Delete "*Specific gravity, Nondestearinated cod liver oil*"

1166	*Glucosamine Tablets*	*Disintegration and dissolution* ⟨2040⟩	Line 8: Change "*Phosphate buffer*, *Mobile phase*, and *Chromatographic system*—Proceed as directed in the *Assay* under *Glucosamine Hydrochloride*." to: *Phosphate buffer*—Mix 1.0 mL of phosphoric acid with 2 L of water, and adjust with potassium hydroxide to a pH of 3.0. *Mobile phase*—Prepare a mixture of *Phosphate buffer* and acetonitrile (3:2). Sonicate for 15 minutes, and pass through a filter of 0.5-µm or finer pore size. Make adjustments if necessary (see *System Suitability* under *Chromatography* ⟨621⟩). *Chromatographic system* (see *Chromatography* ⟨621⟩)—The liquid chromatograph is equipped with a 195-nm detector and a 4.6-mm × 25-cm column that contains packing L7. The flow rate is about 0.6 mL per minute. Chromatograph the *Standard solution*, and record the responses as directed for *Procedure*: the tailing factor for the glucosamine peak is not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%.
1169	*Glutamic Acid*	*Specific rotation* ⟨781S⟩	Line 1 of *Test solution*: Change "6 N" to: 2 N
1598	*Olive Oil*	SPECIFIC TESTS *Fats and Fixed Oils, Sterol Composition* ⟨401⟩	Column 1, row 3 of the table: Change "Δ7-Stigmasterol" to: Δ7-Stigmastenol
1614	*Polydextrose*	IMPURITIES *Procedure 2, Limit of Monomers*	Column 1, row 5 of *Table 1*: Change "1,6-Anhydro-D-glucose (D-anhydroglucose furanose form)" to: 1,6-Anhydro-D-glucose (D-anhydroglucose pyranose form)
1822	*Aluminum Subacetate Topical Solution*	Chemical Information	Line 1: Delete "  $C_4H_7AlO_5$ 162.08 Aluminum, bis(acetato-*O*)hydroxy-. Bis(acetato)hydroxyaluminum. Basic aluminum acetate [*142-03-0; 8000-61-1*]."
1870	*Amitriptyline Hydrochloride*	*USP Reference standards* ⟨11⟩	Line 4 of *USP Amitriptyline Related Compound B RS*: Change "$C_{20}H_{25}O$" to: $C_{20}H_{25}NO$
1969	*Azithromycin for Injection*	*pH* ⟨781⟩	Change "*pH* ⟨781⟩" to: *pH* ⟨791⟩
1972	*Azithromycin Tablets*	PERFORMANCE TESTS *Dissolution* ⟨711⟩	Line 1 of *Diluent*: Change "17.5 mg/mL of dibasic potassium phosphate. Adjust with phosphoric acid to a pH of 8.00 ± 0.05." to: 17.5 mg/mL of dibasic potassium phosphate. Adjust with phosphoric acid to a pH of 8.00 ± 0.05. Prepare a mixture of this solution and acetonitrile (80:20).
2125	*Calcium Acetate*	*Limit of fluoride*	Line 2: Change "*Dibasic Calcium Phosphate*" to: *Dibasic Calcium Phosphate Dihydrate*
2145	*Calcium Undecylenate*	*Particle size*	Change "*Particle size, Method 1* ⟨786⟩" to: *Particle size* ⟨786⟩
2217	*Cefepime Hydrochloride*	*Limit of N-methylpyrrolidine*	Line 4 of *Chromatographic system*: Change "4.4-mm × 5-cm guard column" to: 4.6-mm × 5-cm guard column
2272	*Cetirizine Hydrochloride and Pseudoephedrine Hydrocholoride Extended-Release Tablets*	PERFORMANCE TESTS *Dissolution* ⟨711⟩	Line 15 of *System suitability*: Change "C_S = concentration of cetirizine hydrochloride in the *Standard solution*" to: C_S = concentration of cetirizine hydrochloride in the *Standard solution* (mg/mL)
			Line 31: Change "C_S = concentration of pseudoephedrine in the *Standard solution*" to: C_S = concentration of pseudoephedrine hydrochloride in the *Standard solution* (mg/mL)

2304	*Chloroquine Phosphate*	*Assay*	Line 3 of *Chromatographic system*: Change "3.5-mm × 10-cm column" to: 4.6-mm × 10-cm column
2354	*Citalopram Tablets*	IMPURITIES *Organic Impurities*	Line 7 of *Sample solution*: Change "Dilute as necessary to obtain a final concentration of 0.5 mg/mL of citalopram." to: Dilute with *Mobile phase* as necessary to obtain a final concentration of 0.5 mg/mL of citalopram.
2408	*Clotrimazole*	ASSAY *Procedure*	Delete: "*Sample stock solution*: Transfer 100 mg of Clotrimazole to a 10-mL volumetric flask, add 5 mL of methanol to dissolve, add 2.5 mL of *Buffer*, and dilute with methanol to volume."
2453	*Cyclophosphamide*	*Assay*	Line 1 of *Relative standard deviation*: Change "NMT 2% from six replicate injections" to: NMT 2% from six replicate injections, cyclophosphamide peak
		SPECIFIC TESTS *Limit of Phosphate*	Line 1 of *Sample solution*: Change "1 g/L of Cyclophosphamide in water" to: Dissolve 100 mg of Cyclophosphamide in water, and dilute to 100 mL.
2615	*Docetaxel*	IMPURITIES *Organic Impurities*	Line 2 of *System suitability*: Delete "*Standard solution,*"
		Impurity Table 1	Column 3, row 7: Change "—" to: 1.0
2634	*Doxepin Hydrochloride*	*USP Reference standards*⟨11⟩	Line 1 of *USP Doxepin Related Compound A RS*: Change "5-(4-Nitrophenyl)-2-furaldehyde-2-carboxymethyl semicarbazone." to: Dibenzo[*b,e*]oxepin-11(6*H*)-one.
4046	*Propofol*	*USP Reference standards* ⟨11⟩	Line 3 of *USP Propofol Related Compound A*: Add "$C_{24}H_{34}O_2$ 354.53"
			Line 3 of *USP Propofol Related Compound B*: Add "$C_{12}H_{16}O_2$ 192.25"
			Line 2 of *USP Propofol Related Compound C*: Change "2,6 Diisopropylphenylisopropyl ether. $C_{14}H_{22}O$ 206.32" to: 2,6-Diisopropylphenyl isopropyl ether. $C_{15}H_{24}O$ 220.35
4117	*Ramipril Capsules*	IDENTIFICATION A. *Ultraviolet Absorption* ⟨197U⟩	Line 10: Add "*Path length*: 0.1-cm cell"
		IMPURITIES *Organic Impurities*	Line 1 of *Signal-to-noise ratio*: Change "for each peak" to: for the ramipril peak
4178	*Rivastigmine Tartrate Capsules*	PERFORMANCE TESTS *Dissolution* ⟨711⟩	Line 1 of *Standard solution*: Change "0.192 mg/mL of USP Rivastigmine Tartrate RS in *Mobile phase*" to: 0.192 mg/mL of USP Rivastigmine Tartrate RS in *Mobile phase*. Further dilute with *Medium* to obtain a solution having a concentration similar to that expected in the *Sample solution*.
4205	*Scopolamine Hydrobromide Injection*	*Assay*	Line 1 of *Chromatographic system*: Change "The gas chromatograph contains a 2-mm × 1.8-m glass column packed with 3% liquid phase G3 on support S1AB." to: The gas chromatograph is equipped with a flame-ionization detector and a 2-mm × 1.8-m glass column packed with 3% liquid phase G3 on support S1AB.
4635	*Zolpidem Tartrate Tablets*	IMPURITIES *Organic Impurities*	Line 1 of *Standard solution*: Change "USP Zolpidem Hydrochloride RS" to: USP Zolpidem Tartrate RS
First Supplement to USP34–NF29			
4798	*Thymol*	CAS Number	Line 1: Change "*[89-83-3]*" to: *[89-83-8]*

4894	*S-Adenosyl-L-methionine Disulfate Tosylate*	DEFINITION	Line 3: Change "It contains NLT 95.0% and NMT 105.0% of *S*-adenosyl-L-methionine ($C_{15}H_{23}N_6O_5S^+$), calculated on the anhydrous basis." to: It contains NLT 95.0% and NMT 105.0% of *S*-adenosyl-L-methionine disulfate tosylate ($C_{22}H_{34}N_6O_{16}S_4$) calculated through the content of *S*-adenosyl-L-methionine ($C_{15}H_{23}N_6O_5S^+$), calculated on the anhydrous basis.
4906	*Succinic Acid*	IMPURITIES *Heavy Metals, Method I* ⟨231⟩	Change "2 ppm" to: NMT 20 ppm
		SPECIFIC TESTS *Melting Range or Temperature* ⟨741⟩	Change "185°–190°" to: 185.0°–190.0°
4925	*Cefdinir Capsules*	IMPURITIES *Organic Impurities*	Column 4, row 22 of *Impurity Table 1*: Change "—" to: 0.05
4933	*Cephalexin Tablets for Oral Suspension*	ASSAY *Procedure*	Line 8 of *Analysis*: Change "C_S = concentration of USP Cephalexin RS in the *Sample stock solution* (mg/mL)" to: C_S = concentration of USP Cephalexin RS in the *Standard stock solution* (mg/mL)
4938	*Citalopram Oral Solution*	IMPURITIES *Organic Impurities*	Line 2 of *Buffer*: Change "5 mL of tetra-n-butyl ammonium hydroxide (40% aqueous solution)" to: 5 mL of tetra-*n*-butyl ammonium hydroxide, 40 percent in water
4967	*Glyburide Tablets*	PERFORMANCE TESTS *Test 4*, *Dissolution* ⟨711⟩	Line 1 of *Standard solution*: Change "2.8 µg" to: 2.8 µg/mL
4978	*Levalbuterol Hydrochloride*	IMPURITIES *Residue on Ignition* ⟨281⟩	Change "NMT 0.10%" to: NMT 0.1%
		Procedure 2: Enantiomeric Purity and Chiral Identity	Line 2 of *System suitability solution A*: Change "0.40 µg" to: 0.40 µg/mL
4983	*Lopinavir*	IMPURITIES *Organic Impurities, Procedure 2*	Line 1 of *Sample solution*: Change "0.025 mg/mL in *Diluent*" to: 0.5 mg/mL in *Diluent*
5016	*Oxycodone Hydrochloride*	ASSAY *Procedure*	Line 1 of *Mobile phase*: Change "Sodium 1-hexanesulfonate" to: 0.005 M sodium 1-hexanesulfonate
5043	*Terazosin Capsules*	IMPURITIES *Organic Impurities*	Line 2 of *Buffer*: Change "heptane sulfonic acid sodium salt monohydrate" to: sodium 1-heptanesulfonate monohydrate
			Line 1 of *Relative standard deviation*: Change "NLT 2.0%" to: NMT 2.0%
5045	*Terazosin Tablets*	IMPURITIES *Organic Impurities*	Line 2 of *Buffer*: Change "heptane sulfonic acid sodium salt monohydrate" to: sodium 1-heptanesulfonate monohydrate
		IMPURITIES *Organic Impurities*	Line 1 of *Relative standard deviation*: Change "NLT 2.0%" to: NMT 2.0%